Skip Navigation


ToxSci Advance Access originally published online on September 1, 2004
Toxicological Sciences 2005 83(2):282-292; doi:10.1093/toxsci/kfh264
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow All Versions of this Article:
83/2/282    most recent
kfh264v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sawada, H.
Right arrow Articles by Asahi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sawada, H.
Right arrow Articles by Asahi, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences vol. 83 no. 2 © Society of Toxicology 2005; all rights reserved.

HIGHLIGHTED ARTICLE

A Toxicogenomic Approach to Drug-Induced Phospholipidosis: Analysis of Its Induction Mechanism and Establishment of a Novel in Vitro Screening System

Hiroshi Sawada*,1, Kenji Takami{dagger} and Satoru Asahi{ddagger}

* Biomedical Research Laboratories, {dagger} Discovery Research Center, and {ddagger} Development Research Center, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka 532-8686, Japan

Received August 2, 2004; accepted August 8, 2004

Phospholipidosis is a lipid storage disorder in which excess phospholipids accumulate within cells. Some cationic amphiphilic compounds are known to have the potential to induce phospholipidosis. This study was undertaken to examine the molecular mechanisms that contribute to the development of phospholipidosis and to identify specific markers that might form the basis of an in vitro screening test. Specifically, we performed a large-scale gene expression analysis using DNA microarrays on human hepatoma HepG2 cells after they were treated with each of 12 compounds known to induce phospholipidosis. In electron microscopy, HepG2 cells developed lamellar myelin-like bodies in their lysosomes, the characteristic change of phospholipidosis, after treatment with these compounds for 72 h. DNA microarray analysis performed 6 and 24 h after treatment showed alterations in gene expression reflecting the inhibition of lysosomal phospholipase activity and lysosomal enzyme transport, and the induction of phospholipid and cholesterol biosynthesis. Seventeen genes that showed a similar expression profile following treatment were selected as candidate markers. Real-time PCR analysis confirmed that 12 gene markers showed significant concordance with lamellar myelin-like body formation. Furthermore, the average fold change values of these markers correlated well with the magnitude of this pathological change. In conclusion, microarray analysis revealed that factors such as alterations in lysosomal function and cholesterol metabolism were involved in the induction of phospholipidosis. Furthermore, comprehensive gene expression analysis enabled us to identify biomarkers of this condition that we then used to develop a rapid and sensitive in vitro screening test for drug-induced phospholipidosis.

Key Words: drug-induced phospholipidosis; DNA microarray; real-time PCR; HepG2 cells; toxicogenomics; in vitro screening test.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Brief Funct Genomic ProteomicHome page
B. A. Merrick
The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research
Brief Funct Genomic Proteomic, February 12, 2008; (2008) eln004v1.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
P. Nioi, B. K. Perry, E.-J. Wang, Y.-Z. Gu, and R. D. Snyder
In Vitro Detection of Drug-Induced Phospholipidosis Using Gene Expression and Fluorescent Phospholipid Based Methodologies
Toxicol. Sci., September 1, 2007; 99(1): 162 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
F. Atienzar, H. Gerets, S. Dufrane, K. Tilmant, M. Cornet, S. Dhalluin, B. Ruty, G. Rose, and M. Canning
Determination of Phospholipidosis Potential Based on Gene Expression Analysis in HepG2 Cells
Toxicol. Sci., March 1, 2007; 96(1): 101 - 114.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan
Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release
J Biomol Screen, October 1, 2006; 11(7): 792 - 806.
[Abstract] [PDF]

Home page
 Toxicol SciHome page
T. Kasahara, K. Tomita, H. Murano, T. Harada, K. Tsubakimoto, T. Ogihara, S. Ohnishi, and C. Kakinuma
Establishment of an In Vitro High-Throughput Screening Assay for Detecting Phospholipidosis-Inducing Potential
Toxicol. Sci., March 1, 2006; 90(1): 133 - 141.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.